IntroductionCardiac sarcoidosis (CS) is an infiltrative heart disease caused by granulomatous inflammation in the myocardium. About 5% of individuals with sarcoidosis exhibit noticeable cardiac involvement. Typical manifestations consist of severe conduction disorders, ventricular arrhythmias (VAs), or dysfunction of the left ventricle (LV) 3. To assess the probability of a person having CS, a blend of multimodal imaging and collaborative efforts across various disciplines is essential. ECG and echocardiography possess limited sensitivity. Cardiac magnetic resonance (CMR) imaging and fluorine-18 fluorodeoxyglucose (FDG)–positron emission tomography (PET) are essential imaging techniques for the precise diagnosis of CS3.Current data show that the prognosis of cardiac sarcoidosis (CS) has significantly improved with the use of implantable cardioverter-defibrillators and modern heart failure treatment. Recently, the quantity of people with implantable cardioverter-defibrillator (ICD) devices for inherited cardiomyopathy and congenital heart conditions has risen significantly. Consequently, several women of childbearing age now have such devices, prompting inquiry into whether these patients face a higher risk of negative outcomes or complications during pregnancy and presenting a significant challenge in managing pregnancy.